Digoxin DAK 62.5 mikrog Norge - norsk - Statens legemiddelverk

digoxin dak 62.5 mikrog

2care4 aps - digoksin - tablett - 62.5 mikrog

Digoxin Orifarm 62.5 mikrog Norge - norsk - Statens legemiddelverk

digoxin orifarm 62.5 mikrog

orifarm healthcare a/s - digoksin - tablett - 62.5 mikrog

Digoxin Orifarm 250 mikrog Norge - norsk - Statens legemiddelverk

digoxin orifarm 250 mikrog

orifarm healthcare a/s - digoksin - tablett - 250 mikrog

Digoxin DAK 62.5 mikrog Norge - norsk - Statens legemiddelverk

digoxin dak 62.5 mikrog

orifarm as - digoksin - tablett - 62.5 mikrog

Adcirca (previously Tadalafil Lilly) Den europeiske union - norsk - EMA (European Medicines Agency)

adcirca (previously tadalafil lilly)

eli lilly nederland b.v. - tadalafil - hypertensjon, pulmonal - urologika - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. effekt har blitt vist i idiopatisk pah (ipah) og i pah relatert til kollagenvaskulær sykdom. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

Adempas Den europeiske union - norsk - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Lariam 250 mg Norge - norsk - Statens legemiddelverk

lariam 250 mg

cheplapharm arzneimittel gmbh - meflokinhydroklorid - tablett - 250 mg

Malarone 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

malarone 250 mg / 100 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg

Malarone Junior 62.5 mg / 25 mg Norge - norsk - Statens legemiddelverk

malarone junior 62.5 mg / 25 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 62.5 mg / 25 mg

Provaqomyl 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

provaqomyl 250 mg / 100 mg

viatris limited - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg